Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin

Chung Feng Huang, Jee Fu Huang, Jeng Fu Yang, Ming Yen Hsieh, Zu Yau Lin, Shinn Cherng Chen, Liang Yen Wang, Suh Hang Hank Juo, Ku Chung Chen, Wan Long Chuang, Hsing Tao Kuo, Chia Yen Dai, Ming Lung Yu

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Background & Aims: A substantial proportion of hepatitis C virus genotype 1 (HCV-1) patients achieved a sustained virological response (SVR, HCV RNA seronegative throughout 24 weeks of post-treatment follow-up) after 24 weeks peginterferon/ribavirin therapy. We explored the role of interleukin-28B genotype in identifying patients who responded to the regimen. Methods: Interleukin-28B rs8099917 genotype was determined in 226 HCV-1 patients with 24 weeks peginterferon/ribavirin. Results: Compared to patients with rs8099917 TG/GG genotype, those with TT genotype had significantly higher rapid virological response (RVR, HCV RNA seronegative at treatment week 4, 54.0% vs. 17.9%, p

Original languageEnglish
Pages (from-to)34-40
Number of pages7
JournalJournal of Hepatology
Volume56
Issue number1
DOIs
Publication statusPublished - Jan 2012
Externally publishedYes

    Fingerprint

Keywords

  • HCV
  • IL-28B
  • Tailored regimen
  • Treatment

ASJC Scopus subject areas

  • Hepatology

Cite this

Huang, C. F., Huang, J. F., Yang, J. F., Hsieh, M. Y., Lin, Z. Y., Chen, S. C., Wang, L. Y., Juo, S. H. H., Chen, K. C., Chuang, W. L., Kuo, H. T., Dai, C. Y., & Yu, M. L. (2012). Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. Journal of Hepatology, 56(1), 34-40. https://doi.org/10.1016/j.jhep.2011.03.029